Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]
In development
Reference number: GID-TA11214
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early October 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early December 2024.